In tumors with KRAS mutations (especially those with TP53 mutations) and BRAF non‐V600E mutations, the use of ICBs can provide clinical benefits; however, tumor mutations such as EGFR, ALK, and MET are usually unresponsive to ICBs,[3] showing resistance and escape. This evidence concerns the gene EGFR and neoplasm.